The Impact of Widespread RSV Vaccination and Quantifying Results
In the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.
There are now 3 FDA-approved RSV vaccines for seniors. Throughout this series we have looked at the efficacy, safety, and mechanism of action of the immunizations. Now it is time to look at the big picture perspective and identify what RSV vaccination means on a larger scale.
In our new short series titled, Special Report: Clinical Insights on Moderna's RSV Vaccine, Ann Falsey, MD, professor of Medicine at the University Of Rochester School Of Medicine, and Edward Walsh, MD, also a professor of Medicine at the University Of Rochester School Of Medicine
have a peer-to-peer discussion on the impact these vaccines may have in preventing this respiratory illness.
In this fourth and final episode, Falsey and Walsh discuss what it will take to measure the impact of these vaccines and some of the other important takeaways regarding these newer prophylactic modalities.
